Decitabine (NSC 127716)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

97 publications

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Size Price Stock Quantity  
10mM (1mL in DMSO) GBP 126 In stock
GBP 73 In stock
GBP 139 In stock
GBP 262 In stock
GBP 466 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Decitabine (NSC 127716) has been cited by 97 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NVHLOnU5TnWwY4Tpc44hSXO|YYm= MXSwMlXDqM7:TR?= M4XwPFI1KGh? MWP3ZZRmeg>? NFT0Z|Bud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? NF\oXJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 NH3SSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LldFAvPS9{LkWvOUDPxE1? NHTDWG4zPC92OD:3NkBp M3zwUJdifGW{ Mki5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NUDXU4F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 NVnweFY2TnWwY4Tpc44hSXO|YYm= MmTYNE42yqEQvF2= NGjzWJE3NzF{L{K0JIg> MlnZe4F1\XJ? Mn3ObY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 MlraSpVv[3Srb36gRZN{[Xl? MYqwMlXDqM7:TR?= MYCyOEBp NU\pWmVNf2G2ZYK= MVPpcohq[mm2czDj[YxtKGmwdnHzbY9v NWHzeJVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 M4e0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;DO|AvPcLizszN NVLlUIQ1OjRiaB?= M4DheZdifGW{ NUXJT3BIcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 MV7GeY5kfGmxbjDBd5NigQ>? M{DDeFAvPS9zIN88US=> NWqyd21LOjRiaB?= MmDYe4F1\XJ? M2XJfYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MljOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116  M{PsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzFepcxNjVxMT:yM|Uh|ryP M3jiTFQ5KGh? NWLyUpgzTE2VTx?= NWDiW2lV\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M2fQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XwRlAvPS9zL{KvOUDPxE1? MUS0PEBp M1KyR2ROW09? NXvGeWt3\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NGPwTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  MXfGeY5kfGmxbjDBd5NigQ>? M{DZNVExKM7:TR?= M4Th[lQ5KGh? NV:3eWJjTE2VTx?= M{HJU4lv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO MlLRSpVv[3Srb36gRZN{[Xl? NXvnUmhCOTBizszN MXO0PEBp NWD4S3N[TE2VTx?= MmTWbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116  MmDkRZBweHSxc3nzJGF{e2G7 NXvwS|FVOTBizszN M4nUXVQ5KGh? MnvOSG1UVw>? M3PVZYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO NFvEOnhCeG:ydH;zbZMhSXO|YYm= MWCxNEDPxE1? MoLsOFghcA>? NH20SWxFVVOR M3zpdoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 NHPtSlFCeG:ydH;zbZMhSXO|YYm= M{LLUlEwOiEQvF2= M3f3b|Q5Nzd{L{m2JIg> MofhSG1UVw>? NV3NVm1bcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  MlrBRZBweHSxc3nzJGF{e2G7 NVjqTFdXOS9{IN88US=> MXu3Nk86Pi9zMkCgbC=> MnTrSG1UVw>? M3W4XYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3\hc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  MlfTRZBweHSxc3nzJGF{e2G7 MYiwMlUwOSEQvF2= NXzLW4o6OjRxNEigbC=> MVnEUXNQ Mmf5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3LNVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
NCI-H929  M3\pZ2Fxd3C2b4Ppd{BCe3OjeR?= M1S4flEwOiEQvF2= NFGxSnk4Oi97Nj:xNlAhcA>? MlLuSG1UVw>? NEPCOlBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIGwcXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
RPMI-8226 NV\rR|I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDiNU8zKM7:TR?= M3fxOlI1NzR6L{eyJIg> M3PU[mROW09? M3nFNYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NX\3WnhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
OPM-2  Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxM|Ih|ryP NWj6OIFqOjRxNEivO|IhcA>? NWjWXZZuTE2VTx?= NYrVeHl{[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  NXn1OHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVewMlUwOSEQvF2= NHvwNlQzPC92OD:3NkBp MX3EUXNQ NE\JUFVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
NCI-H929  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\qNU8zKM7:TR?= NEfyUnozPC92OD:3NkBp MlXaSG1UVw>? MWjh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa NGro[llMcW6jc3WgRZN{[Xl? NInLNIdMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy MlTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa MYnLbY5ie2ViQYPzZZk> MUDLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= NHLJfHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa M1:yOWtqdmG|ZTDBd5NigQ>? NEjFdmVMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NVzoXIJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa M2XxOWtqdmG|ZTDBd5NigQ>? M3HuR2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> M3OwTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
NB4 NH:y[mpHfW6ldHnvckBCe3OjeR?= MnHHNk42NzVxNz61M|ExKM7:TR?= MknCNlQhcA>? NWHqbopKTE2VTx?= MWnpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OES4O|AoRjJ2NEi0PFcxRC:jPh?=
CD4+ CD25− T  MXrGeY5kfGmxbjDBd5NigQ>? NXTVPFRpOS93IN88US=> NUjr[3p5emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w M3HGZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N|YxLz5{NES3OlM3ODxxYU6=
BV-173 NXvoVpB3SXCxcITvd4l{KEG|c3H5 MYOwMlI2NzBwNT:wMlc2NzFizszN M136eVQ5Nzd{L{m2JIg> MYRCpHBDWw>? MkD3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NFfReIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 NWnpToI2SXCxcITvd4l{KEG|c3H5 M1Hwc|AvOjVxMD61M|AvPzVxMTFOwG0> NV;zeWd2PDhxN{KvPVYhcA>? MkXpxsBRSlN? NEfVNJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NUfVNJZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 M3\rVGFxd3C2b4Ppd{BCe3OjeR?= MkDONE4zPS9yLkWvNE44PS9zIN88US=> NF3he2w1QC95Mj:5OkBp MXJCpHBDWw>? MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M33ZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
KG-1a NVX4RotNSXCxcITvd4l{KEG|c3H5 M3PX[|AvOjVxMD61M|AvPzVxMTFOwG0> MVm0PE84Oi97NjDo M2ThPeKhWEKV Mn;vbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
BV-173 M3LiPWZ2dmO2aX;uJGF{e2G7 MlrLNlUxNzVyMH7N NILoO4M1QCCq NXrTRnNCyqCSQmO= MlTnbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NFPtXmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
CEM MXzGeY5kfGmxbjDBd5NigQ>? NYj0[G5XOjVyL{WwNI5O MXK0PEBp NVfpNHh1yqCSQmO= M3fDe4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NWTIcXhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 M1XKdWZ2dmO2aX;uJGF{e2G7 NV;idHZQOjVyL{WwNI5O MmHoOFghcA>? NXTEXWI5yqCSQmO= MXvpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NULjdoRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
ML-1 NG\XeZpHfW6ldHnvckBCe3OjeR?= MXiyOVAwPTBybl2= MlrYOFghcA>? MX1CpHBDWw>? NGO2eG9qdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M4D1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
DLD-1 MUTGeY5kfGmxbjDBd5NigQ>? NYnPe4lPOjVyL{WwNI5O MlLJOFghcA>? NVrvcZplyqCSQmO= NHn4RoVldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M2Ho[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HCT-116 NV;DSHBMTnWwY4Tpc44hSXO|YYm= Mlu5NlUxNzVyMH7N MWi0PEBp NUTBXnpvyqCSQmO= MYnkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18  MV7BdI9xfG:|aYOgRZN{[Xl? NGXS[GoxNjBzL{CuNU8yNzFyIN88US=> NFrDVGQ1QCCq MW\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF;oNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOwNFQ2Pid-MkSzNFA1PTZ:L3G+
HT29 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[3NkBp M2foPWlEPTB;MUSwNOKyOTd7IN88US=> MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48 NIjTVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TdlczKGh? NYfMN4RpUUN3ME2xOU4zyrF4LkKg{txO NVzaZlVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
HCT116 NITDTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnVNnMyPzJiaB?= M1nOcWlEPTB;MT63xtExNjRizszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HepG2 NGPHTJhHfW6ldHnvckBCe3OjeR?= NY[yT3NSOC53L{Gg{txO NYHqdpg{OjRiaB?= MY\EUXNQ NEXBcIp2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T MXjGeY5kfGmxbjDBd5NigQ>? MnXHNE42NzFizszN NEXVZXkzPCCq MW\EUXNQ MnHEcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= M2G5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2 Ml\uRZBweHSxc3nzJGF{e2G7 NVjqToM3OS9zMD:xNFAh|ryP MnX4O{Bl NI\OR2VFVVOR Mn7PbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEHNcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
LS174T NF7iUWVCeG:ydH;zbZMhSXO|YYm= NYrQeJNqOS9zMD:xNFAh|ryP NXLnVHdsPyCm MoDmSG1UVw>? M2\Wd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1qwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939 NIHtO4pCeG:ydH;zbZMhSXO|YYm= M3jaWlEwOTBxMUCwJO69VQ>? MWC3JIQ> NIX2OVJFVVOR MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
U251 NH\XTmpCeG:ydH;zbZMhSXO|YYm= NYjrcJkxOS9zMD:xNFAh|ryP NF7qbWU4KGR? NHSyTYVFVVOR MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
HL-60 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHFNUDPxE1? Mmi3OFghcA>? NGnmTXNqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= NYDNUZhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFA{OjRpPkK0NFAxOzJ2PD;hQi=>
MDA‑MB‑453 NVLhNoxSTnWwY4Tpc44hSXO|YYm= M3SxW|AvOi9zIN88US=> MUG3NkBp NXXmclU4[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569 Mn7USpVv[3Srb36gRZN{[Xl? NWjVVZVTOC5{L{Gg{txO NFHodYI4OiCq M{SzbINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
BT‑474 NV7kfoFPTnWwY4Tpc44hSXO|YYm= MVOwMlIwOSEQvF2= MVK3NkBp MnXlZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NGPQ[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
AGS MYDBdI9xfG:|aYOgRZN{[Xl? MUG1M|ExNzJyL{WwJO69VQ>? MoHKOFjDqGkEoB?= M13PN2ROW09? M1jkTIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
A549 NX:1VGJuSXCxcITvd4l{KEG|c3H5 NXnpNGQyPS9zMD:yNE82OCEQvF2= MkLzOFjDqGkEoB?= NYLF[JBUTE2VTx?= NH3sO4RqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? M1rEV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
AGS  MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK1M|ExNzJyL{WwJO69VQ>? MUC0POKhcMLi MnL4SG1UVw>? MVPpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NES5bGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
Kasumi-1 M4\QZWFxd3C2b4Ppd{BCe3OjeR?= NVvXWoREOC53IN88US=> NVjDNItiPDkEoHlCpC=> NV75fpp[\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7M{O0PEc,OjN2OUOzOFg9N2F-
OCI-AML3 MlPRRZBweHSxc3nzJGF{e2G7 MWqyMlUh|ryP MYG0POKhcMLi NGH3dGtl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> M4DoSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
MV4-11 MoS1RZBweHSxc3nzJGF{e2G7 M3PjXFIvPSEQvF2= Ml;lOFjDqGkEoB?= NVHRUnUz\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NWLUS49LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
NK  MYjDfZRwfG:6aYT5JGF{e2G7 MlrTNE4xOi1{MDFOwG0> NVq4[I5sPSCm MmDl[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? M1;HblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
NK  MUTBdI9xfG:|aYOgRZN{[Xl? NEjjTpAxNjB{LUKwJO69VQ>? MnnhOUBl M1;qVYRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? NFO5dGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK  M4n3eGZ2dmO2aX;uJGF{e2G7 M2rDSFAvODFvMkCg{txO NFm5O202KGR? NXzpNpg{[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? NFrmb4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
MOLT4/DNR MoPzSpVv[3Srb36gRZN{[Xl? MXq1JO69VQ>? NG\5UIE1KGR? NIrIcW1z\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NYLaTIFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX M1;VNGZ2dmO2aX;uJGF{e2G7 MlnlOUDPxE1? NGXrUVU1KGR? MofIdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NEfNWZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
MOLT4/DNR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPBemg2KM7:TR?= NWnMdlhTPCCm MoTwdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= M{HQ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX NX3oZ4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv6TXhNPSEQvF2= M3TBcVQh\A>? NXG0WnVsemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M3HQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC  M4rRbmFxd3C2b4Ppd{BCe3OjeR?= MnjCNE4xOS1zMN88US=> M1zESFczKGh? MlPUSG1UVw>? M4ju[YhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NGj4PWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  MUDBdI9xfG:|aYOgRZN{[Xl? NHuzdHYxNjBzLUGw{txO M1H6dFczKGh? M{i1WWROW09? MXjoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498 MVLBdI9xfG:|aYOgRZN{[Xl? NXPRZ45pOC5yMT2xNO69VQ>? NIn3WIg4OiCq MYrEUXNQ NVrhdXRmcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NEjz[Zc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
KIJ265T NIKz[pBCeG:ydH;zbZMhSXO|YYm= NWnZOnF[OC5yMT2xNO69VQ>? MYK3NkBp MV\EUXNQ MYXpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NEKwSGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
MDA-231 MlvCRZBweHSxc3nzJGF{e2G7 MUSwMlAyNTFyzszN NHW0ZZM4OiCq MWfEUXNQ Mo\PbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3nQXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
BT-20 MlnCRZBweHSxc3nzJGF{e2G7 M2XKVlAvODFvMUFOwG0> NF;KbI84OiCq NUPBR|JwTE2VTx?= MYnpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NV;2WYVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DI[|UuOjBizszN NHLmd3AzPC92OD:3NkBp NV\PS2JRcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NUi5TXZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
HL60 M4LsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW1MVIxKM7:TR?= M{PaVVI1NzR6L{eyJIg> MVfpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M3nw[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
U937 MV7BdI9xfG:|aYOgRZN{[Xl? M3H2O|E2KM7:TR?= NXrUVJJwOjRxNEivO|IhcA>? NUHx[FFDcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYizcHFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
HL60 NEm4N2JCeG:ydH;zbZMhSXO|YYm= M3LPb|E2KM7:TR?= MkTmNlQwPDhxN{KgbC=> MVLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N  M{XEUmFxd3C2b4Ppd{BCe3OjeR?= NH;OOGkxNjVizszN NGnrVo84OiCq NVHGWoN4cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NkG2PVUoRjJ{NE[xOlk2RC:jPh?=
MDA-MB-231 MUTBdI9xfG:|aYOgRZN{[Xl? MmLGNVAh|ryP MXq0PEBp NV;ad4ViemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
MCF-7  NYr6OFNySXCxcITvd4l{KEG|c3H5 Mon5NVAh|ryP M4jEZ|Q5KGh? M1HXZpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFO1fY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4O|Y6Pyd-MkG4PFc3QTd:L3G+
A375 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;JNE42KM7:TR?= NGPFSoQyNzVxODDk NFfVNmhqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL1 NWSz[YcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOxU4QxNjVizszN M3PHbVEwPS96IHS= M4rkdolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M2XGU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\SXFAvPSEQvF2= NYnneHh2OS93L{ig[C=> MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL28 NGDafWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;rcGs3OC53IN88US=> MVSxM|UwQCCm NXHYNVA4cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo NYDZcGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXVNE42KM7:TR?= NX7kUWRmOS93L{ig[C=> M1LDN4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
B16 M1fW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2wMlUh|ryP NF;qcnEyNzVxODDk MkGzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MnvsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
Ly 1 M{LqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojHNlQhcA>? NW\zcFg{UUN3ME23MlMh|ryP NVGy[W1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf0T5N7OjRiaB?= NH7DO4VKSzVyPUGwMlch|ryP MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 NWjKfoczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXNlQhcA>? M2H2dmlEPTExvK6yNEDPxE1? NWHBXHB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxWVI1KGh? NYDB[Gs3UUN3MP-8olIxKM7:TR?= MljqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA NUL5VFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:yOEBp MnL5TWM2OO,:nkKwJO69VQ>? M3zsR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 NX;lOHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiyOEBp M1;lU2lEPTExvK6yNEDPxE1? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXkOFghcA>? M3;MS2lEPTB;MD6zOEDPxE1? M3:4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 M2PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm2N5g1QCCq NHPMPHlKSzVyPUCuNFI2KM7:TR?= NF7ufJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3GfJc1QCCq NWHCTXNZUUN3MP-8olIxKM7:TR?= MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XlN|Q5KGh? MWjJR|UxRTFwODFOwG0> M3P1Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA NV7zcZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jFR|Q5KGh? MXXJR|Ux97zgMkCg{txO M{PEXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSyWoo1QCCq NEX1dVRKSzVyPUG3MlQh|ryP NWHKVYJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 1 M17mN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PTPFczKGh? MmLQTWM2OD1yLkCxJO69VQ>? M3nMe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT4WpR7PzJiaB?= NXXDcXRHUUN3ME2wMlAyQCEQvF2= NX;j[JBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL6 NFvOe21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzO|IhcA>? NF;xUlBKSzVyPUGuOkDPxE1? NE\tU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 10 NIC0SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37SWFczKGh? NHHVNmNKSzVyPUGuNkDPxE1? Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA M3vjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NkBp MVTJR|Ux97zgMkCg{txO MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NHq4dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4XpA4OiCq NX\0O4pXUUN3ME2xNU4zKM7:TR?= M4jWNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI Mmn2RY51cX[rcnHsJIF{e2G7 NGjudXUxNjJ3IITvJFghfU1? M{HEVFIhfG9iN{KgbJJ{ NGOxV41CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHU2NWejZzDs[ZZmdCCjdDCwMlI2KHSxIEigeW0h[W[2ZYKgNkB1dyB5MjDodpMh[nlicWDDVkBu\XSqb3S= NWDNcIFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI MWPBcpRqfmm{YXygZZN{[Xl? MlziNE4zPSC2bzC4JJVO MljyNkB1dyB5MjDodpM> NXvX[YJFSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBo[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m M{juZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine (NSC 127716) | Decitabine (NSC 127716) supplier | purchase Decitabine (NSC 127716) | Decitabine (NSC 127716) cost | Decitabine (NSC 127716) manufacturer | order Decitabine (NSC 127716) | Decitabine (NSC 127716) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID